Cancer Clinical Trials

Clinical trials are research studies in which people help doctors find ways to improve health and cancer care. Each study tries to answer scientific questions and to find better ways to prevent, diagnose or treat cancer. Learn more about the different types and phases of clinical trials.

Why should I participate in a clinical trial?

Today it is possible to enroll in a clinical trial as the first step in your treatment after a cancer diagnosis. There are literally hundreds of trials available across the country. In fact, many of our most effective treatments used today for breast, colon, rectal and childhood cancers are the result of recent successes in clinical trials. As a participant a patient has the opportunity to help further the cause for other cancer patients, and possibly be helped by the treatments they receive. Participation in a clinical trial is voluntary. 

Below is a listing current treatment clinical trials for cancer offered through the Genesis Cancer Care Institute and Iowa Cancer Specialists. See clinical trials offered by Hematology-Oncology Associates of the Quad-Cities, PC

Each trial below is linked to a complete description provided by the National Cancer Institute. If you need assistance with this process, contact us

You may search for other clinical trials through the following links: National Cancer Institute Clinical Trial Search; Emerging Med; Trial Check; or Center Watch.

Showing 1-10 of 21

Sorted By:

  • Breast Cancer: CALGB 49907 (Hematology Oncology Associates)

    To compare the effectiveness of standard chemotherapy regimens (Cyclophosphamide, Methotrexate and Fluorouracil [CMF] or Doxorubicin and Cyclophosphamide [AC]) with single agent Capecitabine with respect to disease-free survival in women 65 years and older with local and regional breast cancer.

  • Breast Cancer: CTSU E5103 (Hematology Oncology Associates)

    The purpose of this study is to determine if adding a medication by the name of bevacizumab to the current standard chemotherapy of cancer-reducing medications, namely doxorubicin, cyclophosphamide and paclitaxel, reduces the risk of recurrence (called disease-free survival) compared to standard chemotherapy alone.

  • Breast Cancer: CTSU E5103 (Iowa Cancer Specialists)

    The purpose of this study is to determine if adding a medication by the name of bevacizumab to the current standard chemotherapy of cancer-reducing medications, namely doxorubicin, cyclophosphamide and paclitaxel, reduces the risk of recurrence (called disease-free survival) compared to standard chemotherapy alone.

  • Breast Cancer: N063D (Hematology Oncology Associates)

    This purpose of this research study is to find out what effects (good and bad) the study treatment has on patients with early stage HER2 positive (HER2+) breast cancer that has been surgically removed.

  • Breast Cancer: NSABP B-43 (Iowa Cancer Specialists)

    This study is being done to compare the effects, good and bad, of adding the drug trastuzumab (also called Herceptin®) to breast radiation therapy. Radiation therapy is the standard treatment for patients with ductal carcinoma in situ (DCIS).

  • Breast Cancer: NSABP B-47 (Iowa Cancer Specialists)

    The main purpose of this study is to learn if adding a targeted therapy, trastuzumab (Herceptin®), to standard treatment with chemotherapy for early stage, HER2-low breast cancer, will prevent breast cancer from returning.

  • Breast Cancer: PACCT-1 (Hematology Oncology Associates)

    The purpose of this study is to determine whether patients who have a tumor with an Oncotype DX Recurrence Score of 11-25 benefit from chemotherapy, and to confirm that patients who have Oncotype DX Recurrence Score of < 10 have a very low risk of recurrence with hormonal therapy alone (and do not need chemotherapy to reduce their risk of recurrence).

  • Breast Cancer: PACCT-1 (Iowa Cancer Specialists)

    The purpose of this study is to determine whether patients who have a tumor with an Oncotype DX Recurrence Score of 11-25 benefit from chemotherapy, and to confirm that patients who have Oncotype DX Recurrence Score of < 10 have a very low risk of recurrence with hormonal therapy alone (and do not need chemotherapy to reduce their risk of recurrence).

  • Breast Cancer: S1007 (Iowa Cancer Specialists)

    The purpose of this study is to determine the effect of chemotherapy in patients with node positive breast cancer who do not have high Recurrence Scores (RS) by Oncotype DX.

  • Breast Cancer: SWOG S0221 (Hematology Oncology Associates)

    The main purpose of this study is to compare the effects (good and bad) of two different treatments (or “regimens”) for breast cancer that is considered high risk. These two treatments include essentially the same drugs given in different ways and on different schedules. All of the treatments use standard, commercially available medicines that are known to be effective for treating breast cancer.

Page InfoPage
Page of 3, showing trials 1-10 of 21

Contact Us

For more information about our cancer services, please contact:

563-421-1900

800-446-6088

or contact us online

Related Locations

Cancer Navigators

Do you or a loved one have cancer? Let our Cancer Navigators guide the way. Call us today.

563-421-1900

Learn More

Upcoming Classes/Events